New medication offers hope to patients with frequent, uncontrollable seizures

April 18, 2012

A new type of anti-epilepsy medication that selectively targets proteins in the brain that control excitability may significantly reduce seizure frequency in people whose recurrent seizures have been resistant to even the latest medications, new Johns Hopkins-led research suggests.

"Many other drugs to treat frequent seizures have been released in the last 10 years and for many people, they just don't work," says study leader Gregory L. Krauss, M.D., a professor of neurology at the Johns Hopkins University School of Medicine. "For a drug-resistant population that has run out of options, this study is good news. These are patients who are tough to treat and are fairly desperate."

Perampanel is the first in a new class of drugs that appears to blunt an excitatory response in the brain by inhibiting a specific form of called an and therefore reducing seizures without causing major side effects. Other drugs targeting all three forms of glutamate receptors in the brain have tended to make patients too sleepy to function, even putting them in comas, Krauss says. But this new medication, he says, may potentially offer relief not only to people with epilepsy, but to those struggling with problems or the ALS.

"For years, people have been trying to modify glutamate receptors to cure disease," he says. "It's been a very difficult area to develop in."

In a multinational, blinded, placebo-controlled trial of more than 700 people with uncontrolled partial-onset seizures, roughly one-third of participants saw the frequency of their seizures fall by more than 50 percent when they were given 8 milligrams a day of perampanel. Partial-onset seizures — the most common form in epilepsy — begin in one part of the brain, occurring when there is an injury or abnormality in one of the brain's electrical networks. They can involve anything from the twitching of a limb to confusion to convulsions. Those in this trial typically had roughly 10 seizures a day at baseline.

One in 200 Americans have epilepsy and more than half have partial-onset seizures.

The participants in the study, being reported this week in the journal Neurology, were all taking one to three anti-epileptic drugs before adding perampanel (or a placebo) to their regimen. Krauss and his colleagues assigned each to receive a placebo, two milligrams, four milligrams or eight milligrams per day of the drug. The lowest effective dose was four milligrams per day and the higher the dose, they found, the better the results. Another trial is currently looking at a 12 milligram per day dose. The most common side effect was dizziness, Krauss says.

Explore further: New drug may reduce seizures in epilepsy

More information: The study was paid for by Eisai Inc., a New Jersey-based pharmaceutical firm. Krauss says he believes the U.S. Food and Drug Administration will review perampanel in the next year.

Related Stories

New drug may reduce seizures in epilepsy

April 13, 2011
A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug. The late-breaking ...

Non-epileptic seizures may be misdiagnosed longer in veterans

September 5, 2011
Psychogenic non-epileptic seizures may go undiagnosed for much longer in veterans compared to civilians, according to a new study published in the September 6, 2011, print issue of Neurology, the medical journal of the American ...

Variation in make-up of generic epilepsy drugs can lead to dosing problems

June 30, 2011
Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly ...

Recommended for you

Want to control your dreams? Here's how

October 19, 2017
New research at the University of Adelaide has found that a specific combination of techniques will increase people's chances of having lucid dreams, in which the dreamer is aware they're dreaming while it's still happening ...

Nature or nurture? Innate social behaviors in the mouse brain

October 18, 2017
Adult male mice have a simple repertoire of innate, or instinctive, social behaviors: When encountering a female, a male mouse will try to mate with it, and when encountering another male, the mouse will attack. The animals ...

Brain activity predicts crowdfunding outcomes better than self-reports

October 18, 2017
Surveys and self-reports are a time-honored way of trying to predict consumer behavior, but they have limitations. People often give socially desirable answers or they simply don't know or remember things clearly.

Navigational view of the brain thanks to powerful X-rays

October 18, 2017
If brain imaging could be compared to Google Earth, neuroscientists would already have a pretty good "satellite view" of the brain, and a great "street view" of neuron details. But navigating how the brain computes is arguably ...

'Wasabi receptor' for pain discovered in flatworms

October 18, 2017
A Northwestern University research team has discovered how scalding heat and tissue injury activate an ancient "pain" receptor in simple animals. The findings could lead to new strategies for analgesic drug design for the ...

Brain-machine interfaces to treat neurological disease

October 18, 2017
Since the 19th century at least, humans have wondered what could be accomplished by linking our brains – smart and flexible but prone to disease and disarray – directly to technology in all its cold, hard precision. Writers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.